NCE-1 Intelligence & Market Opportunity

Pepaxto

Melphalan Flufenamide

Anticancer

Intravenous Powder

Approval Date

26-Feb-21

NCE-1 Date

26-Feb-25

NCE Date

26-Feb-26

Commercial snapshot

Market performance & projections

Revenue ($M)

172

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

185

2027

193

2028

2029

2030

2031

2032

Molecule profile

Details & specifications

Molecule

Melphalan Flufenamide

Innovator

ONCOPEPTIDES AB

Dosage Form

Intravenous Powder

Strength

EQ 20 mg base/vial

Therapeutic Category

Anticancer

Usage

To treat relapsed or refractory multiple myeloma

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.